⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VTVT News
vTv Therapeutics Inc. Class A Common Stock
vTv Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
VTVT
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
globenewswire.com
VTVT
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
globenewswire.com
VTVT
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
VTVT
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
globenewswire.com
VTVT